Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    haematology and oncology

    Palmar-plantar erythrodysaesthesia (supportive care)

    Also known as: Hand–foot syndrome, Palmar-plantar erythrodysesthesia syndrome, Chemotherapy-associated acral erythema, Toxic erythema of the palms and soles

    Palmar-plantar erythrodysaesthesia (PPE), or hand-foot syndrome, is a dermatological toxicity associated with specific antineoplastic agents. Clinical manifestations typically include erythema, dysaesthesia, tenderness, and oedema of the palms and soles, potentially progressing to bullae formation or desquamation. Specific targeted therapies may induce localised hyperkeratotic reactions. These symptoms frequently impair gait and manual dexterity, necessitating oncology review for possible dose modification. Current literature, including trials for rivoceranib and sorafenib, documents severe cutaneous adverse events, though pharmacovigilance data remains insufficient to establish precise incidence or causality. As the cited evidence does not evaluate acupuncture or Chinese herbal medicine (CHM) for this specific indication, TCM pattern differentiation serves solely as a traditional adjunctive framework. It aims to provide symptom-oriented support alongside standard dermatological care and prescribed oncological management.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Utilise well-fitted, non-constrictive footwear, soft hosiery, and cushioned implements to minimise mechanical pressure on affected integument.
    • •Avoid immersion in hot water, vigorous friction, and activities involving repetitive thermal or mechanical stress to the extremities.
    • •Adhere strictly to the moisturising and barrier-protection protocols prescribed by the oncology team; refrain from debriding calluses or lancing bullae.
    • •Maintain a daily clinical log documenting pain intensity, cutaneous changes, and functional capacity (gait and manual dexterity) relative to anticancer treatment-cycle timing.

    Cautions & Contraindications

    See sources
    • •Do not needle through erythema, blisters, fissures, ulcers or suspected infection; avoid local heat, moxibustion and abrasive techniques on affected skin. These are conservative procedural precautions, not interventions tested by the supplied toxicity trial.[]
    • •Defer acupuncture during fever or clinical instability and obtain oncology clearance for neutropenia, thrombocytopenia, anticoagulation or impaired healing. The supplied trial provides oncology safety context but no needling thresholds.[]
    • •Do not introduce herbs during suspected severe drug reactions, unexplained hepatic or renal impairment, or before medication-interaction review. Supplied records report systemic safety signals and liver-test abnormalities but do not evaluate these formulas or establish their interactions.[,]
    • •A widespread blistering or mucosal eruption must not be managed as routine hand–foot syndrome or a TCM heat pattern; defer adjunctive procedures and arrange emergency assessment.[]

    When to reassess or seek care again

    See sources

    Record baseline pain on a 0–10 scale, intact versus broken skin, walking tolerance, grip-related activities and oncology-assigned toxicity grade. For stable mild symptoms, review within 3–7 days and around each treatment cycle. Escalate the same day for new blistering, worsening pain or functional limitation; do not wait for an adjunctive-care review. Stop an adjunct if symptoms worsen or adverse effects occur, and seek oncology review if no functional improvement is evident within one week.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. Frontiers in pharmacology · 2025
    2. Pharmaceuticals (Basel, Switzerland) · 2026
    3. The Lancet. Oncology · 2025
    4. Frontiers in medicine · 2026

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.